Patents by Inventor Seung Bin Cha

Seung Bin Cha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250022308
    Abstract: A display device including: scan lines including first and second scan lines; pixels connected to the scan lines; photo sensors connected to some of the scan lines, the photo sensors including a first photo sensor connected to the first scan line and a readout line, and a second photo sensor connected to the second scan line and the readout line; a scan driver to provide scan signals to the scan lines; and a readout circuit to receive, through the readout line, detection signals which are outputted from the photo sensors in response to the scan signals, wherein, while the scan signals are provided to the first and second scan lines, the readout circuit samples a detection signal of one of the first photo sensor and the second photo sensor without sampling a detection signal of the other one of the first photo sensor and the second photo sensor.
    Type: Application
    Filed: September 30, 2024
    Publication date: January 16, 2025
    Inventors: Il Nam KIM, Seung Hyun MOON, Dong Wook YANG, Hyun Dae LEE, Kang Bin JO, Go Eun CHA, Hee Chul HWANG
  • Patent number: 11491235
    Abstract: The present invention relates to an orally-administered gene carrier and a use thereof, and more specifically, to: an oral gene carrier comprising, at the C-terminus of an immunoglobulin Fc region, a linker formed from cationic arginine and enabling the condensation of an anionic gene; and an oral composition for preventing, ameliorating or treating metabolic diseases, the composition comprising the gene carrier and the GLP-1 gene as active ingredients. The gene carrier, according to the present invention, may be usefully employed as an orally-administered carrier for various genes, and especially, is expected to be usable for preventing, ameliorating or treating metabolic diseases, such as diabetes and obesity, by effectively transferring the GLP-1 gene.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 8, 2022
    Assignee: KB BIOMED INC.
    Inventors: Yong Kyu Lee, Seung Bin Cha, Sung Hun Kang, Sun Hwa Lee
  • Publication number: 20200407407
    Abstract: The present invention relates to an orally-administered gene carrier, and more specifically, to an orally-administered gene carrier having cationic protamine connected to an immunoglobulin Fc region by an SMCC linker, the cationic protamine enabling the condensation of an anionic gene. The orally-administered gene carrier enables protamine, which is a protein having cationic properties, to bind to an Fc region and be condensed with a gene having anionic properties, and thus may effectively induce the in vivo expression of the gene, and when orally administered, may enable the gene to be transferred to the small intestine by protecting the gene from a degradation reaction resulting from an immune action of white blood cells and stomach acid, and may enable the half-life of the gene to be relatively long when the gene is expressed in the small intestine, and thus a potential for a long-term treatment effect has been confirmed.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 31, 2020
    Inventors: Yong Kyu LEE, Seung Bin CHA, Sung Hun KANG, Sun Hwa LEE
  • Publication number: 20200390897
    Abstract: The present invention relates to an orally-administered gene carrier and a use thereof, and more specifically, to: an oral gene carrier comprising, at the C-terminus of an immunoglobulin Fc region, a linker formed from cationic arginine and enabling the condensation of an anionic gene; and an oral composition for preventing, ameliorating or treating metabolic diseases, the composition comprising the gene carrier and the GLP-1 gene as active ingredients. The gene carrier, according to the present invention, may be usefully employed as an orally-administered carrier for various genes, and especially, is expected to be usable for preventing, ameliorating or treating metabolic diseases, such as diabetes and obesity, by effectively transferring the GLP-1 gene.
    Type: Application
    Filed: December 20, 2018
    Publication date: December 17, 2020
    Inventors: Yong Kyu LEE, Seung Bin CHA, Sung Hun KANG, Sun Hwa LEE
  • Patent number: 9879232
    Abstract: The attenuated vaccinia virus strain KVAC103 was obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park, Sang Won Lee
  • Publication number: 20160106829
    Abstract: Disclosed herein is the attenuated vaccinia virus strain KVAC103 obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Inventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park